These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 16109523

  • 1. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Chen JY, Wang LW, Sun XM, Gong ZJ.
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
    [Abstract] [Full Text] [Related]

  • 2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 3. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 4. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Nov; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 5. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 6. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R, Kumashiro R, Murashima S, Ogata K, Tanaka K, Hisamochi A, Hino T, Ide T, Tanaka E, Koga Y, Sata M.
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [Abstract] [Full Text] [Related]

  • 7. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [Abstract] [Full Text] [Related]

  • 8. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 9. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC, Kim HJ, Do JH, Park SM.
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [Abstract] [Full Text] [Related]

  • 10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H, Lv Y, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [Abstract] [Full Text] [Related]

  • 12. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H.
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 15. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
    Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T.
    J Gastroenterol; 2004 Apr; 39(3):260-7. PubMed ID: 15065004
    [Abstract] [Full Text] [Related]

  • 16. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
    Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M.
    J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha.
    Ma JC, Wang LW, Li XJ, Liao YF, Hu XY, Gong ZJ.
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):166-71. PubMed ID: 17374576
    [Abstract] [Full Text] [Related]

  • 19. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [Abstract] [Full Text] [Related]

  • 20. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
    Yuan J, Zhou BP, Gong ZJ, Xu LM, Jiang XL, Mizokami M.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.